Category: Treatment


Overcoming Melanoma Treatment Resistance Research Update

24 August 2022 In Science, Treatment

About half of all patients given cancer immunotherapies do not respond to them, and although targeted therapies often dramatically shrink tumors in most patients, in about three-quarters of those patients, the treatments stop being effective weeks to months after initially killing tumor cells.

Read More


MRA's Latest Research Report: The Melanoma Research Community Reunites

11 August 2022 In Allies & Partnerships, Events, Melanoma Stories, News, Prevention, Science, Treatment

Each year, MRA brings together hundreds of people from across the melanoma research community to exchange ideas, report on scientific progress, celebrate achievements, and mourn our collective losses.

Read More


What Uveal Melanoma Patients Need to Know about KIMMTRAK

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 18 July 2022 In Science, Treatment

You may have heard of KIMMTRAK, a new therapy that recently earned FDA approval for the treatment of metastatic or unresectable uveal melanoma. Uveal melanoma, also called ocular melanoma, is a rare melanoma subtype that affects about 2,500 people each year in the United States. KIMMTRAK is the first drug to earn FDA approval to treat these patients.

Read More


What Melanoma Patients Need to Know about Opdualag

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 23 May 2022 In Science, Treatment

You may have heard of Opdualag, a new therapy that recently earned FDA approval for advanced melanoma. Opdualag, which combines two different immunotherapies into one medicine, is earning attention as an effective – and more easily tolerated – combination therapy.

Read More


MRA Announces $13 Million in Grants to Advance Melanoma Prevention, Detection & Treatment

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 19 May 2022 In News, Prevention, Science, Treatment

Coinciding with Melanoma Awareness Month, the Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced funding for 27 research grants totaling $13,046,774 to support new research aimed at advancing melanoma prevention, diagnosis and treatment.

Read More


Dr. Gary Deng & The Wellness Principles

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 9 May 2022 In Allies & Partnerships, Prevention, Treatment

Gary Deng, MD, PhD – an integrative medicine specialist at Memorial Sloan Kettering Cancer Center – knows this firsthand. And now, for the first time, Dr. Deng is sharing his unique and highly respected wellness approach with everyone through his upcoming book, The Wellness Principles – Cooking for a Healthy Life.

Read More


Unlocking the Potential of Localized Treatments By Better Understanding Treatment Response

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 23 March 2022 In News, Science, Treatment

It’s easy to think of melanoma – or any cancer – in black and white terms. You have it or you don’t, it responds or it’s resistant to treatment, or it grows or it shrinks. However, like most things, the reality is far more complex.

Read More


MRA Applauds Approval of Relatlimab + Nivolumab for the Treatment of Advanced Melanoma

18 March 2022 In News, Science, Treatment

The Melanoma Research Alliance (MRA) welcomed the news today that the U.S. Food & Drug Administration (FDA) has approved Opdualag™, Bristol-Myers Squibb’s new combination immunotherapy for the treatment of advanced melanoma.

Read More


Recordings from MRA's 2022 Patient Forum

16 March 2022 In Allies & Partnerships, Events, Melanoma Stories, News, Policy, Prevention, Science, Treatment

MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, 2022, brought together hundreds of melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provided networking opportunities across the melanoma community.

Read More


New Research Says Immunotherapy Should be First-Line Therapy for Patients with BRAF-Mutant Melanoma

By Cody Barnett, MPH, MRA Director of Communications & Patient Engagement | 2 February 2022 In News, Science, Treatment

While all patients with advanced melanoma can be treated with checkpoint immunotherapies, patients with tumors containing the BRAF mutation can also be treated with targeted therapies. However, until now, doctors have had little prospective data to determine which treatment approach should be started first. A new study led by Dr. Michael Atkins provides practice-changing insight.

Read More


Login

×